Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.

@article{Zhang2013EtoposideIC,
  title={Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.},
  author={Xiaoying Zhang and Yunlong Li and Yanqi Zhang and Xinghua Chen and Cheng Zhang and Li Gao and Peiyan Kong and Yao Liu and Qin Wen and Yunjing Zeng and Qingyu Wang and Yi Su and Chunsen Wang and Sanbin Wang and Zhong Ying Yuan and Lei Gao},
  journal={Leukemia research},
  year={2013},
  volume={37 6},
  pages={657-64}
}
In a well-controlled multi-center randomized trial in southwestern China, 228 patients with refractory or relapsed AML were received a low-dose CAG regimen either with etoposide (E-CAG) or without etoposide (CAG). The complete remission (CR) rate, overall survival (OS) and toxicity were evaluated. Patients with E-CAG had a higher CR rate (71.1% vs. CAG 50.9%, P=0.0002). The tolerability appeared to be equivalent. Patients with CR who underwent allogenic hematopoietic stem cell transplantation… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

Similar Papers

Loading similar papers…